2016 News Releases

2017 | 2016 | 2015
DateTitle 
12/05/16Luminex wins R&D 100 Award for ARIES Systems
54th R&D Awards Honors Top 100 Technologies of the Year AUSTIN, Texas, Dec. 5, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company was awarded the prestigious R&D 100 Award for its ARIES® Systems at the 54th Annual R&D 100 Awards ceremony in November. The R&D 100 Awards, presented by R&D Magazine, is an international competition that honors the 100 best technologies of the year. The award recognizes technologically significant product... 
Printer Friendly Version
11/17/16ARIES System and Flu A/B & RSV Assay Evaluated by Erasmus MC in New Publication
Journal of Clinical Virology Publication Demonstrates Effectiveness and Ease of Use for Routine Testing AUSTIN, Texas, Nov. 17, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the internationally renowned Department of Viroscience at Erasmus Medical Center in Rotterdam, The Netherlands, has evaluated the ARIES® System and Flu A/B & RSV CE-IVD Assay for clinical testing in a recently published study. Erasmus MC is a consultation center for the World Health Or... 
Printer Friendly Version
11/07/16Luminex Corporation To Present At The 28th Annual Piper Jaffray Healthcare Conference
AUSTIN, Texas, Nov. 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 28th Annual Piper Jaffray Healthcare Conference to be held at the Lotte New York Palace November 29 - 30, 2016, in New York, NY. The investor presentation will begin at 7:30 a.m. Eastern time on Tuesday, November 29, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to ... 
Printer Friendly Version
10/31/16Luminex Corporation Reports Third Quarter 2016 Results; Raises Full Year Guidance
AUSTIN, Texas, Oct. 31, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2016.  Financial and operating highlights include the following: Consolidated third quarter revenue of $71.2 million, an 18% increase compared to the third quarter of 2015.  In the third quarter, Nanosphere contributed revenue of $7.4 million, growth of more than 50% over year-ago period. GAAP net income for the third quarter was $2.... 
Printer Friendly Version
10/11/16Luminex Corporation Third Quarter Earnings Release Scheduled for October 31, 2016
AUSTIN, Texas, Oct. 11, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2016 on Monday, October 31, 2016. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2016 on October 31, 2016, at 4:30 p.m. ... 
Printer Friendly Version
08/08/16Luminex Corporation Receives FDA Emergency Use Authorization for Zika Virus Molecular Detection Assay
Commercially available xMAP® MultiFLEX™ Zika RNA Assay, designed by GenArraytion, Inc., detects 6 genetic targets of Zika virus AUSTIN, Texas, Aug. 8, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a multiplex nucleic acid test designed to detect Zika virus RNA in potentially infected patients using their blood serum, plasma, or urine (collected alongside... 
Printer Friendly Version
08/03/16Luminex Corporation Receives FDA Clearance for New Molecular Test for Identification and Differentiation of Influenza A/B and Respiratory Syncytial Virus
PCR-based Assay Runs on the ARIES® System, a Sample to Answer Platform AUSTIN, Texas, Aug. 3, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Flu A/B & RSV Assay. This is the second assay the FDA has cleared for use on the Luminex ARIES® System. The ARIES® Flu A/B & RSV Assay delivers results in less than 2 hours for the detection and differentiation of three key respiratory pathogens: &nb... 
Printer Friendly Version
07/28/16Luminex Corporation Reports Second Quarter 2016 Results
AUSTIN, Texas, July 28, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2016.  Financial and operating highlights for the quarter include the following: Consolidated second quarter revenue of $64.2 million, a 9% increase compared to the second quarter of 2015.  GAAP net income for the second quarter was $5.7 million, or $0.13 per diluted share. Non-GAAP net income for the second quarter was $14.1 million, or $... 
Printer Friendly Version
07/20/16Luminex Corporation Second Quarter Earnings Release Scheduled for July 28; Revision to Conference Call Date/Time
AUSTIN, Texas, July 20, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will now hold a conference call to discuss the second quarter operating highlights and financial results on Friday, July 29, 2016 at 8:30 a.m. Eastern time. This adjustment in call timing was made for the convenience of the investment community. Luminex continues to expect to report results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 after the close of trading. ... 
Printer Friendly Version
07/08/16Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2016
AUSTIN, Texas, July 8, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016. This reporting date is earlier than usual as a result of the timing of the American Association for Clinical Chemistry's annual conference to be held in Philadelphia from July 31 through August 4. A press release announcing the results is scheduled for release after the close of trading on that... 
Printer Friendly Version
07/06/16Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System
ARIES platform extension provides the significant benefits of ARIES for clinical labs with lower throughput requirements AUSTIN, Texas, July 6, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System. Designed for lower throughput clinical labs, the ARIES® M1 System is a fully integrated, sample to answer platform for performing real-time PCR assays. The ARIES M1... 
Printer Friendly Version
06/30/16Luminex Corporation Completes Acquisition of Nanosphere, Inc.
AUSTIN, Texas, June 30, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Luminex has completed its previously announced acquisition of Nanosphere, Inc. (NASDAQ: NSPH). "We are pleased to announce the completion of this transaction and welcome the Nanosphere team to the Luminex family. This transaction creates an exciting opportunity to enhance our four pillars of growth strategy by providing our customers with a wider array of products, increased support and... 
Printer Friendly Version
06/22/16Luminex Corporation To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
AUSTIN, Texas, June 22, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference to be held July 12 -13, 2016, in New York, NY. The investor presentation will begin at 3:30 p.m. Eastern time on Wednesday, July 13, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web a... 
Printer Friendly Version
06/02/16Luminex Corporation Announces Commencement of Tender Offer for All Outstanding Shares of Nanosphere, Inc. Common Stock
AUSTIN, Texas, June 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that its wholly-owned subsidiary Commodore Acquisition, Inc. has commenced its previously announced tender offer to purchase all outstanding shares of common stock of Nanosphere, Inc. (NASDAQ: NSPH) for $1.70 per share in cash. The tender offer is being made pursuant to the Agreement and Plan of Merger entered into and among Luminex, Commodore, and Nanosphere dated May 15, 2016 as subsequentl... 
Printer Friendly Version
06/01/16Luminex Corporation Receives CE-IVD Mark for ARIES Flu A/B & RSV Assay
AUSTIN, Texas, June 1, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD  status under the European Directive on In Vitro Diagnostic Medical Devices for the ARIES® Flu A/B & RSV Assay. Designed for use with the FDA cleared and CE-IVD marked ARIES® System, the ARIES® Flu A/B & RSV Assay is a rapid and accurate method for the detection and differentiation of three key respiratory pathogens: influenza A virus, i... 
Printer Friendly Version
05/26/16Luminex Corporation To Present At Jefferies 2016 Healthcare Conference
AUSTIN, Texas, May 26, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Jefferies 2016 Healthcare Conference to be held June 7-10, 2016, in New York, NY. The investor presentation will begin at 8:30 a.m. Eastern time on Thursday, June 9, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, g... 
Printer Friendly Version
05/23/16Luminex Corporation and Nanosphere, Inc. Provide Update on Acquisition Agreement
AUSTIN, Texas and NORTHBROOK, Ill., May 23, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) announced today that they have entered into an amendment to the definitive agreement under which Luminex will acquire Nanosphere, a leader in the molecular microbiology and molecular diagnostic market.  The purchase price has been increased to $1.70 per share from $1.35 per share in an all cash transaction valued at approximately $77 million.... 
Printer Friendly Version
05/16/16Luminex to Highlight Latest Additions to Product Portfolio at the 2016 Clinical Virology Symposium
Luminex products highlighted in more than 20 poster presentations, and workshop featuring 3 ARIES customers discussing results from their labs AUSTIN, Texas, May 16, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it will highlight the latest additions to its product portfolio at the 32nd Annual Clinical Virology Symposium, a meeting of the American Society for Microbiology, taking place May 19-21 in Daytona Beach, Florida. The new ARIES® System will be featured in s... 
Printer Friendly Version
05/16/16Luminex Corporation Signs Definitive Agreement to Acquire Nanosphere, Inc.
- Acquisition Creates Premier Portfolio of Molecular Testing Solutions - Expands Access to the High-Growth Molecular Microbiology Market - Immediately Accelerates Growth, Accretive to Adjusted Earnings by End of 2017 AUSTIN, Texas and NORTHBROOK, Ill., May 16, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and Nanosphere, Inc. (NASDAQ: NSPH) today announced that the companies have entered into a definitive agreement under which Luminex will acquire Nanosphere, a leader in the... 
Printer Friendly Version
05/02/16Luminex Corporation Reports First Quarter 2016 Results
AUSTIN, Texas, May 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2016.  Financial and operating highlights for the first quarter 2016 include the following: Consolidated first quarter revenue of $63.0 million, a 9 percent increase compared to the first quarter of 2015, including record assay and royalty revenues; and system revenue that grew 39 percent over the first quarter of 2015. Consolidate... 
Printer Friendly Version
04/28/16Luminex Corporation To Present At Investment Conferences In May
AUSTIN, Texas, April 28, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at two upcoming investment conferences in May: The Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12 at 8:40am PT in Las Vegas The UBS Global Healthcare Conference on Tuesday, May 24 at 9:00am ET in New York City These investor presentations will be webcast live and may be accessed at Luminex Corporation's website at http... 
Printer Friendly Version
04/14/16Luminex Corporation Receives FDA Clearance and CE Mark for SYNCT Software
Single Interface for Luminex Data Provides Lab Directors Streamlined Workflow, Improved Data Management, and the Ability to Easily Add New Functionality with Minimal Validation AUSTIN, Texas, April 14, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that its SYNCT™ Software has received both U.S. Food and Drug Administration (FDA) clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System. SYNCT Software is middleware that pr... 
Printer Friendly Version
04/11/16Luminex Corporation First Quarter Earnings Release Scheduled for May 2, 2016
AUSTIN, Texas, April 11, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2016 on Monday, May 2, 2016. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2016 on May 2, 2016, at 4:30 p.m. Eastern time. The ... 
Printer Friendly Version
04/07/16Luminex Corporation to Showcase CE-IVD Marked ARIES System, Revolutionary Software, and Assays at ECCMID Annual Meeting
1 Podium Talk and 9 Posters Featuring Luminex Products for Infectious Disease Applications will be Presented AUSTIN, Texas, April 7, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will showcase its recently CE-IVD marked, sample to answer ARIES® molecular diagnostic system and related assays at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Amsterdam April 9-12. The new ARIES® System ... 
Printer Friendly Version
03/21/16Luminex Corporation Receives CE-IVD Mark for ARIES System and ARIES HSV 1&2 Assay
AUSTIN, Texas, March 21, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® System and ARIES® HSV 1&2 Assay. The ARIES® System and ARIES® HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. "We are excited to have received a CE-IVD mark for the ARIES® System and ARIES® HSV 1&2 Assay and look forward to rapidly launching this revolutionary sy... 
Printer Friendly Version
02/25/16Luminex Corporation Announces Collaboration with University of Sao Paulo to Validate Zika Virus Detection Panel
AUSTIN, Texas, Feb. 25, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner, GenArraytion, Inc. The MultiFLEX™ Mosquito-borne Panel is now available as a research use only (RUO) multiplex panel designed to detect multiple disease agents, including the Zika v... 
Printer Friendly Version
02/22/16Luminex Corporation Receives Medical Device License for ARIES System and ARIES HSV 1&2 Assay in Canada
AUSTIN, Texas, Feb. 22, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate, Medical Devices Bureau for the ARIES® System and ARIES® HSV 1&2 Assay. The ARIES® System and HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market. "We are excited to receive medical device licenses for the ARIES® System and the A... 
Printer Friendly Version
02/02/16Luminex Corporation To Present At 2016 Leerink Global Healthcare Conference
AUSTIN, Texas, Feb. 2, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 2016 Leerink Global Healthcare Conference to be held February 10-11, 2016, in New York, NY. The investor presentation will begin at 1:50 p.m. Eastern time on Thursday, February 11, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address... 
Printer Friendly Version
02/01/16Luminex Corporation Reports Fourth Quarter And Full Year 2015 Results
AUSTIN, Texas, Feb. 1, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2015.  Financial and operating highlights for the fourth quarter and full year 2015 include the following: Consolidated fourth quarter revenue of $60.4 million, a 4 percent increase compared to the fourth quarter of 2014; full-year 2015 revenue was $237.7 million, a 5 percent increase over 2014. Fourth quarter assay... 
Printer Friendly Version
01/11/16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 1, 2016
AUSTIN, Texas, Jan. 11, 2016 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the fourth quarter and full year ended December 31, 2015 on Monday, February 1, 2016. A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended December 31, 2015 on ... 
Printer Friendly Version